OKYO Pharma Limited Announces Withdrawal of Public Offering
14 Septiembre 2023 - 7:45AM
OKYO Pharma Limited Announces Withdrawal of Public Offering
OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an
ophthalmology-focused bio-pharmaceutical company which is
developing OK-101 to treat dry eye disease (DED) to address the
significant unmet need in this multi-billion-dollar market, today
announced the withdrawal of its proposed public offering of
ordinary shares and its termination of Freedom Capital Markets as
underwriter. The decision was made in response to changing market
conditions.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About OKYO PharmaOKYO Pharma Limited (Nasdaq:
OKYO) is a life sciences company, focusing on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and chronic pain. For further information, please
visit www.okyopharma.com.
Forward-Looking StatementsCertain statements
made in this announcement are forward-looking statements. These
forward-looking statements are not historical facts but rather are
based on the Company's current expectations, estimates, and
projections about its industry; its beliefs; and assumptions. Words
such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,'
'seeks,' 'estimates,' and similar expressions are intended to
identify forward-looking statements. These statements are not
guarantees of future performance and are subject to known and
unknown risks, uncertainties, and other factors, some of which are
beyond the Company's control, are difficult to predict, and could
cause actual results to differ materially from those expressed or
forecasted in the forward-looking statements. The Company cautions
security holders and prospective security holders not to place
undue reliance on these forward-looking statements, which reflect
the view of the Company only as of the date of this announcement.
The forward-looking statements made in this announcement relate
only to events as of the date on which the statements are made. The
Company will not undertake any obligation to release publicly any
revisions or updates to these forward-looking statements to reflect
events, circumstances, or unanticipated events occurring after the
date of this announcement except as required by law or by any
appropriate regulatory authority.
Enquiries:
OKYO Pharma Limited |
Gary S. Jacob, Chief Executive Officer |
+44 (0)20 7495 2379 |
Investor
Relations |
Paul Spencer |
+44 (0)20 7495 2379 |
|
|
|
Okyo Pharma (LSE:OKYO)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Okyo Pharma (LSE:OKYO)
Gráfica de Acción Histórica
De May 2023 a May 2024